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Objectives: To characterize a comprehensive comorbidity profile and to explore the economic
implications of comorbidity among patients with chronic obstructive pulmonary disease
(COPD).
Methods: This retrospective cohort study analyzed medical claims from the Maryland Medicaid
database. We employed a 1:2 caseecontrol design to select COPD patients (nZ 1388) and
demographically matched controls (nZ 2776) aged 40 to 64 years with 24 months of contin-
uous enrollment. Odds ratios were employed to compare comorbidity differences, including
17 conditions defined by the Charlson Comorbidity Index (CCI) and 6 additional conditions
commonly observed in COPD patients. We estimated the incremental medical utilization and
medical cost by specific condition.
Results: Compared with the controls, Medicaid COPD patients had higher comorbidity burden
and were more likely to have myocardial infarction, congestive heart failure, cerebrovascular
disease, peptic ulcer, mild liver disease, hypertension, sleep apnea, tobacco use, and edema.
COPD patients on average had 24% more medical claims (81.4 vs. 65.4, p< 0.001) and were 33%
more expensive than controls ($7603 vs. $5732, p< 0.001). Ten conditions defined by the CCI
as well as hypertension, tobacco use, and edema were associated with incremental medical
utilization and cost in COPD patients; depression was associated with incremental medical
utilization but not cost.presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual
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698 P.-J. Lin et al.Conclusions: The high burden of comorbidity in COPD patients translates into additional
medical utilization and cost. Effective disease management and treatment protocols are
needed to reduce comorbidity burden. The development of a COPD-specific comorbidity
measure may be used to identify high-risk subgroups and to predict utilization and cost.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive respiratory disease that affects approximately 24
million U.S. adults, including 12 million diagnosed patients
and 12 million undiagnosed.1 COPD is a major cause of
disability and hospitalizations in adults and has remained
the fourth leading cause of death in the U.S. for the past
decade.2 The annual cost of COPD was estimated at $42.6
billion in 2007, with $26.7 billion (63%) attributable to
direct health care costs, in which hospital care accounting
for the largest share ($11.3 billion or 42%).1
Comorbid conditions are highly prevalent among indi-
viduals with COPD. A caseecontrol study in a Dutch primary
care population reported that 73% of COPD patients had
one or more comorbidity, compared to 63% in controls (odds
ratioZ 1.6; 95% confidence interval: 1.10e2.33).3 Data
from a managed care organization showed that COPD
patients on average had 3.7 comorbidities, compared to 1.8
comorbidities for controls (p< 0.001).4 In an analysis of
patients with COPD undergoing pulmonary rehabilitation,
51% reported at least one chronic comorbidity, with meta-
bolic diseases (e.g., systemic hypertension, diabetes and/
or dyslipidaemia) and heart diseases (e.g., chronic heart
failure and/or coronary heart disease) being the most
common conditions (61% and 24%, respectively).5
The impact of comorbidities on COPD patients can be
introduced in different ways, such as association with
higher hospitalization and mortality rates6,7 and poorer
quality of life.8,9 In a cohort of 51,353 patients who were
discharged after an exacerbation of COPD in the Veterans
Affairs health care system during the period of 1999 and
2003, the risk of rehospitalization increased with asthma
and pulmonary hypertension.7 Sin and colleagues reviewed
the role of comorbidities in COPD mortality and found that
certain comorbidities such as cardiovascular diseases and
lung cancer were associated with higher mortality rates in
mild and moderate COPD, whereas respiratory failure was
the main cause of death in more advanced COPD, although
the exact nature of the causal pathways remains unclear.10
In this analysis, we examined the impact of individual
comorbidity and overall disease profile on the medical
utilization and cost of COPD patients because comorbidity
is an important source of elevated economic burden in this
population. In related work, we found that Medicaid COPD
patients who have concomitant sleep apnea (known as the
‘‘overlap syndrome’’11) incurred significantly more medical
utilization and higher medical cost than patients without
sleep apnea.12 Other studies indicate that COPD patients
with concomitant asthma used more medical services and
incurred higher cost than those without asthma based on
data from a Medicaid managed care population13 and
a Medicare Advantage population.14 In another study thatcompared expenditure and utilization patterns of elderly
Medicare beneficiaries with COPD (nZ 42,472) versus all
Medicare beneficiaries (nZ 1,221,615), higher comorbid-
ity, as measured by the Deyo-adapted Charlson Comorbidity
Index (CCI), was associated with higher health care
expenditures.15 As health care costs continue to escalate,
understanding the economic implications associated with
comorbidity can help health plans and providers to develop
disease management programs that can better manage
patients with COPD, improve care coordination, and
potentially reduce cost. In this study, we performed a more
thorough examination of comorbidities than previous
studies, which typically address only limited comorbidities
or explore the economic burden of comorbidity measured
by a composite index such as the CCI. Our investigation
included additional comorbidities that are particularly
relevant to COPD patients. The results can help to inform
efforts to develop a COPD-specific comorbidity measure for
high-risk identification. Using data from a Medicaid pop-
ulation enabled us to explore the economic implications of
comorbidity in a frail population.
Materials and methods
Data source
Data were obtained from the Maryland Medicaid database
for 2001 through 2003, which contained all claims records
for medical inpatient hospitalization, outpatient care, and
physician office visits. During the study period, there were
more than 445,000 Medicaid beneficiaries, representing
approximately 10% of the overall state population. The
Medicaid beneficiaries were disproportionately African
American (>50%) and females (>60%).
Cohort selection
The eligible study population was comprised of Medicaid
beneficiaries who were aged 40 to 64 years on the date of
January 1, 2001, and were enrolled in one of seven con-
tracted managed care organizations. We excluded benefi-
ciaries younger than 40 years of age because they are not at
high risk for COPD; beneficiaries aged 65 and older also
were excluded because they may have been dually enrolled
in Medicaid and Medicare and therefore their claims data
may be incomplete. All sample beneficiaries were required
to have continuous enrollment during the 12 months before
the index date (defined as the date of the first medical
claim with a COPD diagnosis) through the 12 months after
the index date. Medical utilization data were collected
from the index date through the end of the post-index
period. We identified beneficiaries with a COPD diagnosis
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the primary, secondary, or tertiary diagnosis field in their
medical claims during the study period. A total of 7236
beneficiaries met the criteria of having 12 months pre-index
period and 12 months post-index period; of these, 2411
beneficiaries (33.3%) had diagnosed COPD. Then, we
employed a 1:2 case-control design to select 1388 COPD
patients and 2776 demographically matched non-COPD
controls with similar age (5 yrs), sex, and race.
Measures of economic burden
In evaluating the economic burden, resource use was
measured by overall medical utilization (defined as the total
number of service claims) and the total medical cost for
individual categories including physician visits, outpatient
services, and inpatient services. Outpatient care was defined
as a practice within a hospital but not being admitted to the
hospital (i.e., inpatient); physician care was defined as
a practice outside of a hospital. Because the Medicaid
managed care claims data do not contain actual costs for
each service claim, we estimated medical cost by using the
average unit cost for each type of service and imputed the
cost values based on the Medicaid fee schedule.
Measures of comorbidity burden
Comorbidity burden was measured using the CCI with the
Deyo modification16,17 and 6 additional conditions
commonly observed in COPD patients. The CCI originally
was developed as a risk measure of one-year mortality rate
based on hospital chart abstraction.16 The CCI contains 17
categories of comorbidities with each assigned a weight of
1, 2, 3, or 6, reflecting the magnitude of the adjusted
relative risks associated with each comorbidity. The CCI
score then sums the weights for all conditions with a total
maximum score of 33. We created 17 dummy variables
representing each condition category: myocardial infarc-
tion, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary
disease (COPD was removed to avoid double-counting),
rheumatologic disease, peptic ulcer disease, mild liver
disease, diabetes, diabetes with chronic complications,
hemiplegia or paraplegia, renal disease, any malignancy,
moderate or severe liver disease, metastatic solid tumor,
and acquired immune deficiency syndrome (AIDS).
Because some other comorbidities also are commonly
found in COPD patients but are not captured in the CCI, we
created 6 dummy variables to indicate these condi-
tions,3,4,12,18 including hypertension (ICD-9-CM diagnosis
codes: 401.xxe405.xx), depression (ICD-9-CM diagnosis
codes: 296.2x, 296.3x, 311.xx), sleep apnea (ICD-9-CM diag-
nosis codes: 780.51, 780.53), tobacco use (ICD-9-CMdiagnosis
codes: 305.1x, V15.82), edema (ICD-9-CM diagnosis codes:
782.3), and pulmonary heart disease (ICD-9-CM diagnosis
codes: 415.xxe416.xx).
We employed three measures to determine the comor-
bidity burden: (1)meanCCI score, (2) comorbidity prevalence
rates and odds ratios (ORs) from logistic regressions to
describe the odds for a COPD patient of having a particular
comorbid condition relative to the odds for a non-COPDcontrol of having it; and (3) the total numberof comorbidities,
including 17 conditions defined by the CCI and 6 additional
conditions of interest (categorized as 0, 1e2, 3e4, and 5).
Analysis
Chi-square tests were used to compare differences in binary
variables; t-tests were used to compare differences in
continuous variables as appropriate between beneficiaries
with and without COPD. A generalized linear model (GLM)
was performed to estimate the average medical utilization
and cost by specific comorbidity. The dependent variables
included age, sex, race, comorbidity dummies, and interac-
tion terms between COPD and these comorbidities, allowing
the impact of comorbidity to differ between beneficiaries
with and without COPD. The incremental medical utilization
associated with each comorbid condition was calculated by
taking the difference of mean medical utilization between
COPD patients and controls; the same procedure was
repeated for calculating the incremental medical cost.
Results
Baseline characteristics
The demographic characteristics and unadjusted annual
mean medical utilization and cost in the pre-index period
are summarized in Table 1. As a result of matching, COPD
patients and controls had similar demographic character-
istics, with a mean age of 49 years, 78.2% female, and 63.3%
African American. The matched sample was slightly
younger than the original sample before matching and
included more females and African Americans.
Beneficiaries with COPD had significantly higher
medical utilization, as measured by the mean number of
medical claims, than non-COPD controls (90.1 vs. 61.6,
p< 0.001) in the pre-index period. Physician office visits
accounted for the largest share of medical utilization
(61.7% in COPD patients and 64.1% in non-COPD controls).
The mean medical cost also was higher in COPD patients
($8763 vs. $5270, p< 0.001). The largest share of medical
cost was attributed to inpatient care: 53.1% of total
medical cost among COPD patients and 41.5% among non-
COPD controls. Compared to the original sample, the
matched cohorts had slightly higher medical utilization
and higher medical cost.
Comorbidity burden
Beneficiaries with COPD had significantly higher comorbid-
ity burden than controls (mean CCI scoreZ 1.56 vs. 1.37,
pZ 0.004). Among comorbidities included in the CCI, the
prevalence rates of diabetes (27.7%), congestive heart
failure (17.9%), chronic pulmonary disease (15.7%), and
cerebrovascular disease (10.7%) were high in COPD patients
(Table 2). Although these comorbidities also were prevalent
among controls, COPD patients were significantly more
likely to have congestive heart failure (ORZ 2.62; 95%
confidence interval [CI]: 2.15, 3.18) and cerebrovascular
disease (ORZ 1.73; 95% CI: 1.38, 2.18) as well as mild liver
disease (ORZ 1.89; 95% CI: 1.23, 2.91) and myocardial
Table 1 Characteristics of the study sample.
Original sample (nZ 7236) Matched sample (nZ 4164)a







Mean age, years (s.d.) 52.4 (6.7) 49.2 (6.9) 49.3 (6.5) 48.9 (6.6) 0.109
Female, % 66.5 75.5 78.2 78.2 e
Race, %
White 54.3 35.7 32.8 32.8 e
African American 43.0 60.8 63.3 63.3 e
Other 2.7 3.6 3.9 3.9 e
Unadjusted mean number of medical claims
in the post-index period (s.d.)
89.0 (88.4) 61.2 (63.6) 90.1 (86.9) 61.6 (64.3) <0.001
Physician office 56.5 (55.6) 39.4 (39.4) 55.6 (51.7) 39.5 (40.1) <0.001
Inpatient 15.2 (30.3) 7.3 (19.8) 15.9 (31.2) 7.5 (21.0) <0.001
Outpatient 17.2 (25.0) 14.5 (23.4) 18.6 (25.8) 14.6 (22.9) <0.001
Unadjusted mean medical cost
in the post-index period, $ (s.d.)
8453 (11,367) 5212 (7891) 8763 (11,611) 5270 (8121) <0.001
Physician office 2006 (1975) 1397 (1397) 1974 (1834) 1401 (1424) <0.001
Inpatient 4464 (8867) 2147 (5810) 4651 (9146) 2186 (6164) <0.001
Outpatient 1983 (2873) 1668 (2692) 2138 (2971) 1683 (2634) <0.001
COPD: chronic obstructive pulmonary disease; s.d.: standard deviation.
a 1:2 caseecontrol matched on age (5 yrs), sex, and race.
b P-values were derived from comparisons between COPD patients and demographically matched controls without COPD.
700 P.-J. Lin et al.infarction (ORZ 1.55; 95% CI: 1.07, 2.24). The prevalence
rates of other comorbidities included in the CCI did not
differ for COPD patients and controls.
For the six additional comorbidities we assessed,
hypertension was highly prevalence in both groups (63.4%
vs. 56.4%; ORZ 1.34; 95% CI: 1.17, 1.53). COPD patients
were more likely to have sleep apnea (ORZ 3.06; 95% CI:
2.09, 4.47), tobacco use (ORZ 2.18; 95% CI: 1.80, 2.62),
and edema (ORZ 1.49; 95% CI: 1.18, 1.89) than controls.
Depression was prevalent in both cohorts (63.4% vs.
56.4%), but the prevalence rate did not differ between
COPD patients and controls (ORZ 1.11; 95% CI: 0.92,
1.34).
In terms of total number of comorbidities, 50.6% of COPD
patients had 1e2 comorbidities, compared to 55.6% in
controls. However, 28.5% and 8.4% of COPD patients had
3e4 and 5 comorbidities, respectively, compared to 21.8%
and 3.7% in controls. Only 12.5% of COPD patients had none
of the 23 comorbidities examined, compared to 18.9% in
controls (p< 0.001).
Incremental medical utilization and medical cost by
comorbidity
Because of the low prevalence rates (<1%) of dementia,
hemiplegia or paraplegia, renal disease, any malignancy,
metastatic solid tumor, and pulmonary heart disease, we
excluded these comorbidities and calculated adjusted
mean medical utilization and medical cost for the remain-
ing 18 conditions. Overall, COPD patients had 24% higher
medical utilization, measured by number of medical
claims, than controls (81.4 vs. 65.4, p< 0.001), after
controlling for demographic characteristics and comorbid-
ity burden (Table 3). The greatest incremental medicalutilization was attributable to diabetes with chronic
complications (148.3 vs. 81.5, p< 0.001), peptic ulcer
disease (137.7 vs. 88.2, p< 0.001), and mild liver disease
(131.5 vs. 96.4, p< 0.001). All other comorbidities, except
myocardial infarction, malignancy, moderate or severe
liver disease and sleep apnea, were associated with incre-
mental medical utilization.
In terms of incremental medical cost (Table 4), COPD
patients on average were 33% more expensive than controls
($7603 vs. $5732, p< 0.001), after controlling for demo-
graphic characteristics and comorbidity burden. COPD
patients who had diabetes with chronic complications cost
$7755 more than controls (p< 0.001). Peptic ulcer disease
and mild liver disease were associated with $7146
(p< 0.001) and $6050 (p< 0.001) higher medical cost,
respectively, in COPD patients. The following comorbidities
also significantly increased the medical cost for COPD
patients: congestive heart failure, peripheral vascular
disease, cerebrovascular disease, chronic pulmonary
disease, rheumatologic disease, diabetes, AIDS, hyperten-
sion, tobacco use, edema. Although depression was asso-
ciated with incremental medical utilization, COPD patients
with depression did not incur significantly higher medical
cost compared to controls ($9057 vs. $7725, pZ 0.067).
Discussion
In this study, we examined the prevalence rates of 23
comorbid conditions and their economic implications
among Medicaid COPD patients compared to a control group
with similar demographic characteristics. We found that
COPD patients had a substantial comorbidity burden, in
terms of higher CCI score, higher ORs for 9 out of the
23 conditions assessed, and higher total number of
Table 2 Comorbidity prevalence for COPD and matched control cohorts.
Comorbidity (%) COPD (nZ 1388) Control (nZ 2776) Odds ratio (95% CI)
Mean CCI score (s.d.) 1.56 (2.07) 1.37 (2.03) p-valueZ 0.004
Comorbidities included in the CCI
Myocardial infarction 3.75 2.45 1.55 (1.07, 2.24)
Congestive heart failure 17.94 7.71 2.62 (2.15, 3.18)
Peripheral vascular disease 4.83 3.93 1.24 (0.91, 1.69)
Cerebrovascular disease 10.73 6.48 1.73 (1.38, 2.18)
Dementia 0.07 0.18 ea
Chronic pulmonary diseaseb 15.71 15.49 1.02 (0.85, 1.21)
Rheumatologic disease 3.60 4.25 0.84 (0.60, 1.18)
Peptic ulcer disease 3.39 1.98 1.73 (1.17, 2.57)
Mild liver disease 2.95 1.59 1.89 (1.23, 2.91)
Diabetes 27.74 27.56 1.01 (0.87, 1.17)
Diabetes with
chronic complications
3.75 3.49 1.08 (0.76, 1.52)
Hemiplegia or paraplegia 0.58 0.72 ea
Renal disease 0 0 ea
Any malignancy,
including leukemia and lymphoma
5.98 4.90 1.24 (0.93, 1.64)
Moderate or severe liver disease 0.79 0.36 ea
Metastatic solid tumor 0.65 0.68 ea
AIDS 5.55 6.74 0.81 (0.62, 1.07)
Comorbidities not included in the CCI
Hypertension 63.40 56.38 1.34 (1.17, 1.53)
Depression 14.19 12.97 1.11 (0.92, 1.34)
Sleep apnea 4.90 1.66 3.06 (2.09, 4.47)
Tobacco use 18.23 9.29 2.18 (1.80, 2.62)
Edema 9.44 6.52 1.49 (1.18, 1.89)
Pulmonary heart disease 0.22 0 ea





AIDS: acquired immune deficiency syndrome; CCI: Charlson Comorbidity Index; CI: confidence interval; COPD: chronic obstructive
pulmonary disease.
a Odds ratio was not reported because too few patients had this comorbidity.
b Excluding COPD.
Economic implications of comorbidity in COPD 701comorbidities than controls. The high burden of comor-
bidities was associated with incremental medical utilization
and medical cost, suggesting that disease management
interventions are needed to improve care for the compre-
hensive disease burden among COPD patients.
To control for confounding due to comorbidity differ-
ences between groups, researchers have numerous comor-
bidity measures to choose from. The CCI and its adaptations
are by far the most widely used comorbidity measure in
mortality analysis because it was constructed to predict
mortality outcome and because the scores are easy to
compute based on administrative data. However, using the
CCI alone to control for confounding in health utilization
and cost models may not be optimal. Previous economic
evaluations in COPD have used other generic comorbidity
measures, such as the Elixhauser Comorbidity Index19 and
the Comorbidity Symptom Scale,8 but generic measures
(including the CCI) may be limited in their ability to capture
the comorbidity profile specific to the COPD population. We
found that some conditions, such as hypertension,depression, tobacco use and edema, that are not included
in the CCI also may have substantial clinical and economic
implications for COPD patients. Our findings can be used to
identify additional comorbid conditions that are particu-
larly relevant for COPD patients. These comorbid conditions
subsequently can inform efforts to develop a COPD-specific
comorbidity measure, which can be used as a managerial
tool for targeting high-risk patients for more tailored
disease management interventions.
Our data show that hypertension was the most common
condition in both groups: 63% in COPD patients and 56% in
controls, higher than any comorbid conditions included in
the CCI. The hypertension prevalence rates are higher than
previously reported3,4 possibly because our sample was
drawn from a Medicaid population in which African Ameri-
cans account for a greater proportion relative to the
general population, and African Americans have been
shown to be at high risk of hypertension.20 In our sample,
hypertension was associated with higher medical services
claims and higher medical cost in COPD patients. The
Table 3 Incremental medical utilization for COPD and matched control cohorts by comorbidity.
Comorbiditya Adjusted mean medical utilization Incremental utilization P-value
COPD (nZ 1388) Control (nZ 2776)
Overall 81.4 65.4 16.0 <0.001
Comorbidities included in the CCI
Myocardial infarction 106.2 102.8 3.4 0.767
Congestive heart failure 127.8 103.6 24.2 <0.001
Peripheral vascular disease 107.8 84.7 23.1 0.018
Cerebrovascular disease 119.7 102.0 17.7 0.011
Chronic pulmonary diseaseb 91.9 73.6 18.3 <0.001
Rheumatologic disease 114.8 87.1 27.7 0.007
Peptic ulcer disease 137.7 88.2 49.5 <0.001
Mild liver disease 131.5 96.4 35.1 0.014
Diabetes 96.6 77.9 18.7 <0.001
Diabetes with
chronic complications
148.3 81.5 66.8 <0.001
Any malignancy,
including leukemia and lymphoma
122.6 124.2 1.6 0.849
Moderate or severe liver disease 143.4 147.8 4.4 0.879
AIDS 121.5 96.8 24.7 0.003
Comorbidities not included
in the CCI
Hypertension 86.5 69.9 16.6 <0.001
Depression 98.3 80.6 17.7 0.001
Sleep apnea 95.1 84.3 10.8 0.357
Tobacco use 93.9 77.6 16.3 0.003
Edema 116.3 89.3 27.0 <0.001
Note: Medical utilization was measured by the number of service claims.
AIDS: acquired immune deficiency syndrome; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease.
a Six comorbidities with <1% of prevalence were excluded. These conditions were dementia, hemiplegia or paraplegia, renal disease,
moderate or severe liver disease, metastatic solid tumor, and pulmonary heart disease.
b Excluding COPD.
702 P.-J. Lin et al.incremental economic burden may be due to the fact that
hypertension frequently is reported in hospitalized patients
with COPD21 and that inpatient care account for the
majority of medical cost (as observed in our sample).
Managing COPD patients may be especially challenging with
the presence of comorbidities because of their complex
health care needs and taking multiple medications. For
instance, COPD patients may over use systemic cortico-
steroids, which could contribute to increased blood pres-
sure, osteoporosis, diabetes, muscle dysfunction, and
adrenal insufficiency.22
Among the 17 conditions included in the CCI, the prev-
alence rates of congestive heart failure, myocardial
infarction, and cerebrovascular disease were significantly
higher in COPD patients than controls. Congestive heart
failure and cerebrovascular disease also were associated
with high incremental medical utilization and cost in COPD
patients. In a cohort of more than 45,000 COPD patients
enrolled in an integrated health care system, congestive
heart failure was the leading cause of hospitalization, fol-
lowed by myocardial infarction and cerebrovascular disease
among all cardiovascular diseases.23 The age-adjusted
hospitalization risk ratios (RR) for COPD patients compared
to the demographically matched controls were significantly
higher for these comorbidities: congestive heart failure
RRZ 5.55 (95% CI: 4.71, 5.73), myocardial infarctionRRZ 2.14 (95% CI: 1.95, 2.36), and cerebrovascular disease
RRZ 1.51 (95% CI: 1.37, 1.66).23 The associated high
economic implications (as observed in our sample) and high
hospitalization risk suggest that COPD patients with
cardiovascular diseases may be a suitable subgroup for
more tailored interventions and disease management.
Several study limitations are attributable to the nature
of the Medicaid data employed in our study. First, female,
low-income populations and minorities, especially African
Americans, were over-represented in our sample. Some
comorbidities, such as hypertension, may be more preva-
lent in this population. Generalizing our results to other
populations should be made with caution. Second, COPD
commonly is undiagnosed1 and COPD patients could
consume substantial health care services and costs prior to
diagnosis.19,24 The potential non-differential misclassifi-
cation bias due to undiagnosed COPD could weaken the
association between comorbidity and economic burden.
Third, there are inherent limitations, such as coding bias,
in using large administrative claims data. The diagnosis
coded in patients’ claims may be the most important
condition or the condition that is most likely to result in
payment. In our study, sample selection and comorbidity
identification was based on the ICD-9-CM diagnosis codes
recorded in claims files. Due to lacking clinical details
(e.g. pathophysiologic data) in Medicaid claims data, we
Table 4 Incremental medical cost for COPD and matched control cohorts by comorbidity.
Comorbiditya Adjusted mean annual cost, $ Incremental
cost, $
P-value
COPD (nZ 1388) Control (nZ 2776)
Overall 7603 5732 1871 <0.001
Comorbidities included in the CCI
Myocardial infarction 11,791 11,976 185 0.903
Congestive heart failure 14,610 10,862 3748 <0.001
Peripheral vascular disease 11,122 7209 3913 0.003
Cerebrovascular disease 13,184 11,004 2180 0.018
Chronic pulmonary diseaseb 8915 6753 2162 0.002
Rheumatologic disease 10,452 7234 3218 0.019
Peptic ulcer disease 14,350 7204 7146 <0.001
Mild liver disease 14,331 8281 6050 0.001
Diabetes 9127 6696 2431 <0.001
Diabetes with
chronic complications




12,075 11,241 834 0.460
Moderate or severe liver
disease
18,970 23,587 4617 0.226
AIDS 13,160 9586 3574 0.001
Comorbidities not included in the CCI
Hypertension 8021 6200 1821 <0.001
Depression 9057 7725 1332 0.067
Sleep apnea 7155 7203 48 0.975
Tobacco use 9643 6876 2767 <0.001
Edema 11,353 8187 3166 <0.001
AIDS: acquired immune deficiency syndrome; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease.
a 6 Comorbidities with <1% of prevalence were excluded. These conditions were dementia, hemiplegia or paraplegia, renal disease,
moderate or severe liver disease, metastatic solid tumor, and pulmonary heart disease.
b Excluding COPD.
Economic implications of comorbidity in COPD 703were unable to determine the extent to which the diag-
noses were accurate. We also did not have information on
COPD severity, which may lead to underestimate or over-
estimate of the economic burden due to comorbidity
differences. Future research using alternative data sour-
ces, such as COPD registries or retrospective chart
reviews, may be needed to validate our findings. Finally,
our cost estimates were based on the Medicaid fee
schedule for the medical service rendered rather than the
actual costs for each type of service, which were not
available in the Medicaid managed care claims data.
Therefore, our cost estimation can only serve as proxies.
This method is deemed reliable and valid since it draws
cost information from the same Medicaid population.
Our findings highlight the high prevalence rates of
comorbidities in Medicaid COPD patients and the substan-
tial economic implications of comorbidity. Additional
conditions not included in the commonly used CCI, such as
hypertension, depression, tobacco use and edema, may
have substantial economic impact on COPD patients. Future
research is needed to articulate and characterize specific
pathways to high utilization and cost associated with
particular comorbid conditions. The development of
a COPD-specific comorbidity measure may be used to
identify high-risk subgroups and to predict utilization and
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